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Abstract
Background: Clustered protocadherins (PCDHs) map in tandem at human chromosome 5q31 and comprise three
multi-genes clusters: α-, β- and γ-PCDH. The expression of this cluster consists of a complex mechanism involving DNA
hub formation through DNA-CCTC binding factor (CTCF) interaction. Methylation alterations can affect this interaction,
leading to transcriptional dysregulation. In cancer, clustered PCDHs undergo a mechanism of long-range epigenetic
silencing by hypermethylation.
Results: In this study, we detected frequent methylation alterations at CpG islands associated to these clustered PCDHs in
all the solid tumours analysed (colorectal, gastric and biliary tract cancers, pilocytic astrocytoma), but not hematologic
neoplasms such as chronic lymphocytic leukemia. Importantly, several altered CpG islands were associated with CTCF
binding sites. Interestingly, our analysis revealed a hypomethylation event in pilocytic astrocytoma, suggesting that in
neuronal tissue, where PCDHs are highly expressed, these genes become hypomethylated in this type of cancer. On the
other hand, in tissues where PCDHs are lowly expressed, these CpG islands are targeted by DNA methylation. In fact,
PCDH-associated CpG islands resulted hypermethylated in gastrointestinal tumours.
Conclusions: Our study highlighted a strong alteration of the clustered PCDHs methylation pattern in the analysed solid
cancers and suggested these methylation aberrations in the CpG islands associated with PCDH genes as powerful
diagnostic biomarkers.
Keywords: Clustered PCDH, Cancer methylation alteration, CpG islands, CTCF, Low grade glioma, LGG, Pilocytic
astrocytoma, PA, Colorectal carcinoma, CRC, Colorectal adenoma, CRA, Gastric cancer, GC, Biliary tract cancer, BTC, Chronic
lymphocytic leukemia, CLL
Background
Protocadherins (PCDHs) are type I transmembrane pro-
teins containing 6 or 7 extracellular cadherin repeats, struc-
turally similar to cadherins. They are characterized by a
large molecular diversity, are broadly expressed and
participate in cell-cell adhesion, predominantly in the ner-
vous system establishing complex neural circuits [1].
PCDHs are classified as clustered and non-clustered
protocadherins. The clustered PCDHs map in tandem at
human chromosome 5q31 and comprise cluster α, clus-
ter β and cluster γ genes (Human Genome Organization
nomenclature PCDHA@, PCDHB@ and PCDHG@, re-
spectively), whereas the non-clustered PCDHs are dis-
tributed across the genome. A great variety of activities
have been reported for clustered PCDHs. These mole-
cules mediate homophilic interactions like most mem-
bers of the cadherin superfamily [2]. The formation of
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these macromolecular complexes leads to the activation
or inhibition of different signalling pathways through
binding to the cytoplasmic domains of the PCDHs [3].
These transmembrane proteins regulate Wnt/β-catenin
[4], PYK2 and FAK tyrosine kinases (involved in cell ad-
hesion) [5, 6] and mTOR pathways [4], among others.
Wu and Maniatis first described the structure of proto-
cadherin gene clusters [7, 8]. PCDHA and PCDHG gene
clusters consist of variable exons that encode for the
extracellular domain, the transmembrane domain and a
short part of the cytoplasmic domain, and constant exons
that encode for a shared C-terminal domain. In contrast,
PCDHB gene cluster presents exons without a constant
region. As PCDHB exons, each variable exon of PCDHA
and PCDHG has its own promoter that is controlled by
methylation [7, 8]. It has been reported that promoter sto-
chastic choice, due to methylation changes and DNA-
binding factor, and transcript splicing generate Pcdh diver-
sity in neurons [9, 10]. This promoter choice and thus the
transcription of clustered protocadherins depend on a
complex mechanism where the CCTC binding factor
(CTCF) plays an essential role. This zinc finger protein
binds to a conserved sequence element (CSE) and a spe-
cific sequence element (SSE) located in the promoter, and
to the enhancer element, a regulatory region downstream
of each cluster, favouring genome looping [11, 12]. CTCF
recognizes its DNA-binding sites, recruits the cohesion
complex, whose members are Rad21, Smc1, Smc3 and
SA2 [13], and allows the interaction of active promoters
and specific enhancers through the formation of a hub
[12]. Recent works also suggested that the binding of
CTCF to the Pcdha cluster is regulated by transcription of
a long non-coding RNA (lncRNA), initiated at a newly
identified promoter within each Pcdha exon. Transcrip-
tion of this antisense lncRNA mediates DNA demethyla-
tion of the CTCF binding sites, thus promoting CTCF
binding [14]. Guo et al. found that forward-reverse orien-
tation of the CTCF binding sites is also important for
looping formation and enhancer-promoter interactions
leading to cell-specific gene expression [15].
As mentioned before, PCDH expression is controlled
by DNA methylation and its dysregulation is common in
different types of cancer. In cancer pathogenesis, clus-
tered PCDHs undergo a mechanism of long-range epi-
genetic silencing (LRES) by hypermethylation. Clustered
PCDH gene silencing was found not only in tumour cell
lines but also in different types of cancer including cer-
vix, liver, lung, colon, breast and brain [4, 16–18]. Novak
et al. detected hypermethylation and transcription down-
regulation in the three clustered PCDHs in breast cancer
[17]. Other breast cancer studies showed that the abnor-
mal DNA methylation of these gene families could be
the consequence of the reduction of CTCF interaction
with DNA due to CTCF aberrant expression or
mutations in its binding domain [19, 20]. On the other
hand, Guo et al. revealed that promoter methylation pre-
vents or reduces CTCF binding to CSE [12]. Dallosso et
al. also found hypermethylation of the majority of
PCDHA, PCDHB and PCDHG in both adenomas and
colorectal carcinomas, relative to normal tissue [4].
Moreover, these authors demonstrated that selected γ-
PCDH are able to suppress Wnt activity in vitro [21]. In
particular, PCDHGC3 negatively regulates Wnt and
mTOR signalling. Interestingly, PCDHGC3 has been
found highly methylated only in carcinomas and not in
previous stages and has been proposed as a driver for
the progression from adenoma to carcinoma [4]. Thus,
although the role of protocadherins in tumour develop-
ment has not been fully established, it is suggestive that
these proteins are involved in the regulation of key cellular
pathways of cell death and proliferation. More recently,
Liu et al. demonstrated that PCDHGA7 downregulation is
correlated with poor prognosis and KRAS genotypic status
in colorectal cancer [22]. Waha et al. detected hyperme-
thylation in PCDHGA11 in astrocytoma, glioblastoma and
glioma cell lines. Moreover, these authors found a signifi-
cant correlation between PCDHGA11 hypermethylation
and downregulation in astrocytomas and glioma cell lines
[16]. On the other hand, Kawaguchi et al. reported mosaic
methylation and hypomethylation of the CpG islands
(CGIs) associated with Pcdha cluster in mouse neuroblast-
oma cell lines [23]. Other PCDHA@ genes, PCDHA4 and
PCDHA13, have been found frequently hypermethylated
in severe cervical neoplasia [18].
In the present study, we investigated the methylation
status of clustered PCDHs in colorectal, gastric and bil-
iary tract cancers (CRC, GC and BTC, respectively);
pilocytic astrocytoma (PA); and chronic lymphocytic
leukemia (CLL). Our results demonstrate that PCDHs
frequently present alterations in their methylation status
in solid cancers in contrast to blood cancer, suggesting
the methylation alterations of these clustered genes as
possible biomarkers for cancerogenesis.
Methods
Experimental discovery datasets
Our experimental discovery dataset included DNA
methylation data of four solid cancers (PA, CRC, GC
and BTC) and one blood cancer (CLL) as summarized in
Fig. 1. In particular, we analysed the following:
- 20 paediatric PAs, collected as part of the Italian Na-
tional Program of Centralization of Paediatric Brain
Tumour and four normal brain control samples obtained
from temporal lobes of adult healthy individuals submit-
ted to epilepsy routine examination;
- 18 primary CRC and four matched normal samples
collected from the Department of General and Colo-
proctological Surgery, University of Cagliari (Italy); 21
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colorectal adenomas (CRAs) and three matched normal
intestinal mucosa controls obtained from the National
Institute for Cancer Research of Genoa (Italy);
- 22 paired GC and normal samples collected from the
Candiolo Cancer Institute-FPO, IRCCS, University of
Turin (Italy);
- 50 BTCs whose 10 paired tumour and normal sam-
ples, obtained from the Department of Oncology, Uni-
versity of Cagliari (Italy) and the Scientific Institute
Romagnolo for the Study and Treatment of Tumours
(IRST) Srl – IRCCS, Meldola, FC (Italy);
- 18 CLLs and six normal blood control samples col-
lected at the Haematology Department of the A. Businco
Oncology Hospital, Cagliari (Italy).
DNA extraction, bisulfite conversion and methylation
assay
DNA was extracted from PA, CRC, CRA, GC and their
respective normal fresh frozen tissues using DNeasy
Blood & Tissue Kit (Qiagen).
DNA from BTC and matched normal formalin-fixed
and paraffin-embedded (FFPE) samples was carried out
by QIAamp DNA FFPE Tissue kit (Qiagen).
In the CLL study, DNA was isolated from peripheral
whole blood lymphocytes using the DNA extraction 500
arrow® Kit (DiaSorin Ireland Ltd).
DNA quantity of all samples was analysed by spectro-
photometric reading (NanoDrop) and by fluorometric
reading (Quant-iT™ PicoGreen® dsDNA Assay Kit) and
its quality was evaluated by electrophoresis in a 0.8%
agarose gel.
All DNA samples were bisulfite converted using EZ
DNA Methylation Gold Kit™ (Zymo Research).
In the BTC study, DNA extracted from FFPE samples
underwent an additional quality control step using the
Infinium FFPE QC kit (Illumina) prior bisulfite conver-
sion. Subsequently, they were subjected to a restoration
step using the Infinium HD FFPE Restore Kit (Illumina).
Genome-wide methylation analysis was performed by
Illumina Infinium HumanMethylation27 BeadChips
(27K) in PA study, Illumina Infinium HumanMethyla-
tion450 BeadChips (450K) in CRC and CLL studies and
Illumina Infinium methylation EPIC BeadChips in GC
and BTC studies. The number of probes mapping in
PCDHG@ cluster in the different BeadChips are re-
ported in Additional file 1: Figure S1. Further informa-
tion and clinical data are available in Antonelli et al. (PA
study) and Fadda et al. (CRC study) [24, 25].
Methylation analyses
Illumina methylation 27K raw data were analysed as de-
scribed in Antonelli et al. [24]. Differential methylation
levels (Δβ) between PAs and normal brain samples were
Fig. 1 Description of sample sets used for the work. Discovery datasets: cancer samples collected for the study of methylome. In silico datasets:
data used to validate the methylation alterations identified in clustered PCDHs, to explore the overall survival in relation to the identified
aberrations and the correlation between methylation and expression of selected PCDHGs
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calculated by Illumina Custom model, as implemented
in the Illumina GenomeStudio software. We selected
only differentially methylated probes (Δβ values ≥ 0.2 or
≤ − 0.2, i.e. 20% differential methylation level) annotated
in PCDH gene clusters with a p value threshold < 0.001.
Hypermethylation was defined as Δβ values ≥ 0.2 and p
value threshold < 0.001, while hypomethylation was de-
fined as Δβ values ≤ 0.2 and p value threshold < 0.001
Illumina 450K and EPIC raw data were analysed using
RnBeads as previously described [26, 27]. In brief, a dif-
ferential methylation analysis between tumour and nor-
mal control samples was performed for each cancer type
studied (CRC, CLL, GC and BTC). The normalization
for the microarray signals was perfomed by Subset-
quantile Within Array Normalization (SWAN) [28].
Corrected p values (Benjamini & Hochberg) were com-
puted as previously described [26, 27]. In particular,
combined p values were adjusted for the entire CpG
sites on the arrays using false discovery rate (FDR). CpG
loci were annotated according to Illumina Manifest to
obtain a gene list based on HUGO Gene Nomenclature
Committee (HGNC) database. We selected only PCDH-
associated differentially methylated CGIs with Δβ values
≥ 0.2 or ≤ − 0.2 and an adjusted p value < 0.05. Hyperme-
thylation was defined as Δβ values ≥ 0.2 and adjusted p
value < 0.05, while hypomethylation was defined as Δβ
values ≤ 0.2 and adjusted p value < 0.05. Since the results
of this analysis were less robust in adenomas [25], we
used the nominal threshold (p values < 0.05) in CRAs.
Finally, for CRC, CRA, GC and BTC, the mean methy-
lation value of each altered CGI for each sample has
been used in an analysis of UHC and visualized by Bio-
conductor package “ComplexHeatmap” [29].
Contingency table 2 × 1 was used to evaluate the statis-
tical significance between methylation levels and microsatel-
lite instability (MSI) status.
CGI annotations in tables and figures correspond to
UCSC CGI names, indicating the number of CpG sites
included in the CGI.
CTCF binding site analysis
We explored whether the altered CGIs were associated
with the CTCF binding sites. As mentioned before, both re-
gions are included in the promoter [11]. CTCF binding
sites’ genomic coordinates were obtained from ENCODE
database [30]. CTCF binding sites and CGIs were consid-
ered as associated if their distance was lower than 1000 bp.
Power calculation
The power of the methylation analyses was estimated based
on the calculation of mean delta betas and standard devia-
tions using data retrieved from the NCBI Gene Expression
Omnibus (GEO) portal [31] under accession number
GSE48684. Based on this preliminary data, we performed a
two-sample t test power calculation obtaining that a statis-
tical power of 0.8 would be guaranteed by analysing 30
samples in order to detect a differential methylation level of
at least 10%, using a type I error of 10e− 8 (which takes into
account the need to correct for multiple tests).
In silico validation datasets
In silico methylation data from The Cancer Genome
Atlas (TCGA), the NCBI GEO Portal and the Inter-
national Cancer Genome Consortium (IGCG) Data Por-
tal were used to validate the methylation alterations
detected in the different cancer types analysed (Fig. 1).
Methylation β values of the identified altered CGI were
visualized using the web tool TCGA Wanderer [32, 33].
In silico analyses
Additional in silico analyses were conducted using data
from TCGA.
The database DNA Methylation and gene expression
in Human Cancer (MethHC) [34] was used to compare
the methylation status of selected PCDHs (PCDHGC3,
PCDHGC4, PCDHGC5) in different types of cancer.
Xena Functional Genomics Explorer [35] allowed to
perform a survival analysis and to study the correlation
between methylation and expression of PCDHG C-type
in LGG and between the altered N-shelf region or al-
tered CGIs associated with gene promoters and the ex-
pression of these genes in TCGA-LGG, TCGA-
COADREAD, TCGA-STAD and TCGA-CHOL.
Results
PCDH cluster: an aberrantly methylated region in solid
cancer
Differential methylation analyses between cancer and
their respective normal tissue samples were performed
using experimental datasets and the results have been
cross-validated in silico (Fig. 1). Differential methylation
levels (Δβ) revealed that clustered PCDH were aber-
rantly methylated in all the solid cancers analysed. In
fact, hypermethylation of CGIs associated with PCDH
genes was among the most significant methylation alter-
ations detected, even in BTC where methylation differ-
ences between tumour and normal samples were fewer
and less pronounced than in the other cancers analysed.
In CRC, the most altered CGI associated with PCDHG@
was the fouth most hypermethylated CGI and the fifth
most significantly altered CGI among the 74 CGIs found
aberrantly methylated in both CRC and CRA in our pre-
vious study [25]. The most altered PCDHG-associated
CGIs in GC and BTC among the statistically significant
hypermethylated CGIs (adjusted p value < 0.05) were
ranked as 122/522 and 40/48, considering the Δβ, and
28/522 and 13/48, considering the p value, respectively.
Interestingly, we detected a hypomethylation event in
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PCDHG cluster although we did not find any hyper-
methylated CGIs associated with PCDH in pilocytic
astrocytoma. This region was 12/208 most hypomethy-
lated in our discovery set. In contrast, we did not find
any relevant methylation alterations in PCDHs in CLL.
Overall, these data suggest that clustered PCDH methyla-
tion alterations are frequent events during tumorigenesis.
PCDH alterations in pilocytic astrocytoma
We evaluated the methylation status of PCDH cluster in
20 PA and four normal brain samples. We detected
DNA hypomethylation (Δβ value = − 0.285) of a flanking
region of a CGI (chr5:140871064-140872335, CpG 122)
associated with the PCDHG cluster and two CTCF bind-
ing sites (Fig. 2a, b, Table 1) in PAs. The flanking region
of this CGI is associated with PCDHGC5 gene promoter
(Fig. 2a, Table 1). This hypomethylation event was
successfully cross-validated using in silico methylation
data of pilocytic astrocytoma (GSE44684) (Fig. 2c). We
could not investigate the methylation status of the CGI
(chr5:140871064-140872335, CpG 122) since we did not
have enough epigenome coverage using the Illumina
Infinium HumanMethylation27 BeadChips, but in silico
analysis revealed that also this CGI was hypomethylated
in PA (Fig. 2c).
PCDH alterations in colorectal cancer
The differential methylation analysis conducted on 18
CRC and four normal samples revealed four significantly
hypermethylated CGIs related to the PCDHG cluster
(Fig. 3a, b, Table 2). All these altered CGIs, except one
(chr5:140864527-140864748, CpG 22), were associated
with CTCF binding sites (Fig. 3a, Table 2). To elucidate
if these aberrations were early events in cancer process,
Fig. 2 Methylation values obtained from the pilocytic astrocytoma discovery dataset and the in silico data. a Genomic organization of PCDHG@,
including the localization of exons, CGIs (annotated with the UCSC CGI names) and CTCF binding sites. b Mean β values, resulting from the
average of the samples (normal and tumour), of each probe obtained using Infinium HumanMethylation27 BeadChip. These two probes
correspond to the N-shelf region of the CpG 122 (chr5:140871064-140872335), altered in our analysis. c Mean methylation values of each probe,
belonging to the CpG 122 (green) and to its flanking region (black), obtained from the in silico dataset GSE44684. The red arrows indicate the
two probes used in our experimental study
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we also performed a differential methylation analysis on
21 CRA and three control mucosae. This analysis re-
vealed methylations alterations in the same CGIs altered
in CRC (Fig. 3b, Table 2). Three altered CGIs mapped to
promoter regions (Fig. 3a, Table 2). Of note, one of these
CGIs (chr5: 140892913-140893189, CpG 20) was not as-
sociated with PCDH@ according to Illumina Manifest
since it is located downstream the cluster and upstream
DIAPH1 gene. Nevertheless, we considered this altered
CGI because it was significantly hypermethylated in both
CRA and CRC. In general, the Δβ values were higher in
carcinomas than in adenomas. On the contrary, one CGI
(chr5:140750050-140750264, CpG 16) presented DNA
methylation differences only in CRA samples (Table 2).
The CGI located at chr5:140864527-140864748 (CpG 22)
presented the highest differential methylation values in both
Table 1 Altered CGI flanking region in pilocytic astrocytoma
UCSC CGI UCSC
CGI
name
CTCF binding
site
Relation
to UCSC
CGI
Δβ value
(PA-
control)
Genes within region Gene
promoter-
associated N-
shelf
chr5:140871064-
140872335
CpG
122
chr5:140870147-
140872480
N-shelf − 0.285 PCDHGA1, PCDHGA10, PCDHGA11, PCDHGA12, PCDHGA2,
PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7,
PCDHGA8, PCDHGA9, PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4,
PCDHGB5, PCDHGB6, PCDHGB7, PCDHGC3, PCDHGC4, PCDHGC5
PCDHGC5
chr5:140871308-
140873492
Note: CGI CpG island, PA pilocytic astrocytoma. CpG 122 corresponds to UCSC CGI name
Fig. 3 Methylation values obtained from the colorectal cancer discovery dataset and the in silico datasets. a Genomic organization of PCDHG@,
including the localization of exons, CGIs (annotated with the UCSC CGI names) and CTCF binding sites. b Mean β values, resulting from the
average of the samples (normal and tumour) of each probe of the altered CGIs obtained using Infinium HumanMethylation450 BeadChip. c Mean
methylation values of each probe, belonging to the CpG 16, CpG 95, CpG 19, CpG 22 and CpG 20 (green), obtained from the in silico datasets
TCGA-COAD and TCGA-READ
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Table 2 Altered CGIs in colorectal cancer and colorectal adenoma
UCSC CGI UCSC
CGI
name
CTCF binding
site
Δβ value
(CRC-
control)
Δβ value
(CRA-
control)
Genes within region Gene
promoter-
associated
CGI
chr5:140750050-
140750264
CpG
16
chr5:140748521-
140750945
0.157* 0.200 PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGB1,
PCDHGB2, PCDHGB3
PCDHGB3
chr5:140855386-
140856620
CpG
95
chr5:140854218-
140856648
0.200* 0.105 PCDHGA1, PCDHGA10, PCDHGA11, PCDHGA12, PCDHGA2, PCDHGA3,
PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9,
PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5, PCDHGB6,
PCDHGB7, PCDHGC3
PCDHGC3
chr5:140857864-
140858065
CpG
19
chr5:140856882-
140859319
0.310 0.259 PCDHGA1, PCDHGA10, PCDHGA11, PCDHGA12, PCDHGA2, PCDHGA3,
PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9,
PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5, PCDHGB6,
PCDHGB7, PCDHGC3
–
chr5:140864527-
140864748
CpG
22
– 0.435 0.277 PCDHGA1, PCDHGA10, PCDHGA11, PCDHGA12, PCDHGA2, PCDHGA3,
PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9,
PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5, PCDHGB6,
PCDHGB7, PCDHGC3, PCDHGC4
PCDHGC4
chr5:140892914-
140893189
CpG
20
chr5:140890901-
140893291
0.302 0.200 – –
chr5:140891594-
140893806
Note: CGI CpG island, CRC colorectal cancer, CRA colorectal adenoma. *Nominal threshold (p value < 0.05). CpG 16, 95, 19, 22 and 20 correspond to
UCSC CGI name
Fig. 4 Colon discovery set unsupervised hierarchical clustering analysis based on the average methylation β value for each of the aberrantly
methylated CGI. Heatmap obtained by UHC of CRC, CRA, CRC-matched normals and CRA-matched normals. All CRCs branched in a same group
separated from control samples, except for sample 279T. Adenomas samples clustered randomly, 12 of them branched along CRCs and the
others resembled the methylation status of normal samples. No correlation was observed between methylation profile and localization/subtype/
staging in CRCs and CRAs. To the right of the heatmap, further information are reported: histology, localization, MSI status, Dukes and grade. CRC
colorectal cancer, CRA colorectal adenoma, MSI microsatellite instability, WT wild-type
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tumour stages, i.e. Δβ value = 0.435 and 0.277, in CRC and
CRA, respectively. Finally, beta values of the altered CGIs
were visualized in a heatmap (Fig. 4). Unsupervised hier-
archical clustering (UHC) showed a clear distinction be-
tween CRC and normal samples, except for 279T. In
contrast, while 12 adenoma samples branched along with
CRC samples, the methylation pattern of the other nine re-
sembled that of normal samples. No association was ob-
served between methylation values and clinical data (Fig. 4).
We successfully validated all the aforementioned
CGI alterations in data from TCGA (TCGA-COAD,
TCGA-READ) (Fig. 3c). We observed that one CGI
(chr5:140855386-140856620, CpG 95) was hyper-
methylated in COAD but not READ samples, with
the exception of the most telomeric part of the CGI
(cg04453180, cg07445963) (Fig. 3c). We observed the
same methylation pattern in our discovery set. In
general, the average CGI beta value was lower (0.125)
in rectal cancer samples than in colon cancer samples
(0.277). Moreover, this CGI presented lower
methylation values in CRC than those observed in the
other altered CGIs (Fig. 3, Fig. 4).
PCDH alterations in gastric cancer
The differential methylation analysis between 22 gastric
tumour and their matched normal samples revealed four
significantly hypermethylated CGIs that were associated
with CTCF binding sites, with the exception of CpG 22,
and mapped to promoter regions (Fig. 5a, b, Table 3).
These alterations were successfully cross-validated in
silico using the TCGA stomach adenocarcinoma dataset
(TCGA-STAD) (Fig. 5c). Of note, two of these CGI
(CpG 22 and CpG 95) were also altered in CRCs. CpG
95 showed a similar methylation pattern as that ob-
served in CRC, with low β values compared to the other
altered CGIs (Fig. 5). UHC analysis allowed to distin-
guish a group of tumours (N = 7) characterized by high
methylation values in all the altered CGIs, a group of tu-
mours (N = 5) that branched along with normal samples
and a third group of tumours (N = 10) whose alterations
Fig. 5 Methylation values obtained from the gastric cancer discovery dataset and the in silico dataset. a Genomic organization of PCDHG@,
including the localization of exons, CGIs (annotated with the UCSC CGI name) and CTCF binding sites. b Mean β values, resulting from the
average of the samples (normal and tumour), of each probe of the altered CGIs obtained using EPIC array. c Mean methylation values of each
probe, belonging to the CpG 28, CpG 45, CpG 95 and CpG 22, obtained from the in silico datasets TCGA-STAD (450K array)
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were intermediate between these two groups (Fig. 6). To
note, eight out of nine MSI (microsatellite instability)
samples were in the clusters of sole tumours and the
remaining one clustered with the normal samples (Fig.
6). Thus, MSI was significantly more frequent in the
group of tumours with high methylation values (p value
= 2.0E− 02). To validate these results, we performed a
UHC analysis using in silico TCGA-STAD methylation
data for the four altered CGIs of samples with available
molecular subtype categorization (N = 248). UHC re-
vealed two clusters of tumours with different methylation
levels (Fig. 7). In particular, 47 out of 49 MSI samples
branched within the cluster displaying high methylation
values, confirming that MSI-positive samples were strongly
Table 3 Altered CGIs in gastric cancer
UCSC CGI UCSC
CGI
name
CTCF binding
site
Δβ
value
(GC-
control)
Genes within region Gene promoter-
associated CGI
chr5:140762401-
140762768
CpG 28 chr5:140761029-
140763470
0.241 PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7,
PCDHGB1, PCDHGB2, PCDHGB3
PCDHGA7
chr5:140787447-
140788044
CpG 45 chr5:140786247-
140788714
0.210 PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA4, PCDHGA5, PCDHGA6, PCDHGA7,
PCDHGA8, PCDHGA9, PCDHGB1, PCDHGB2, PCDHGB3, PCDHGB4, PCDHGB5,
PCDHGB6
PCDHGB6
chr5:140855386-
140856620
CpG 95 chr5:140854218-
140856648
0.212 PCDHGA1, PCDHGA10, PCDHGA11, PCDHGA12, PCDHGA2, PCDHGA3, PCDHGA4,
PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9, PCDHGB1, PCDHGB2,
PCDHGB3, PCDHGB4, PCDHGB5, PCDHGB6, PCDHGB7, PCDHGC3
PCDHGC3
chr5:140864527-
140864748
CpG 22 – 0.243 PCDHGA1, PCDHGA10, PCDHGA11, PCDHGA12, PCDHGA2, PCDHGA3, PCDHGA4,
PCDHGA5, PCDHGA6, PCDHGA7, PCDHGA8, PCDHGA9, PCDHGB1, PCDHGB2,
PCDHGB3, PCDHGB4, PCDHGB5, PCDHGB6, PCDHGB7, PCDHGC3, PCDHGC4
PCDHGC4
Note: CGI CpG island, GC gastric cancer. CpG 28, 45, 95 and 22 correspond to UCSC CGI name
Fig. 6 Gastric discovery set unsupervised hierarchical clustering analysis based on the average methylation β value for each of the aberrantly
methylated CGI. Heatmap obtained by UHC of 22 gastric cancer samples and their matched normal samples. A group of GC with high methylation
values branched together separated from normal samples and few GC samples that resembled the methylation pattern of controls. The UHC analysis
also revealed another group of GC with a methylation profile between normal and tumour samples. To the right of the heatmap, further information
are reported: histology, localization and subtype. GC gastric cancer, MSI microsatellite instability, CIN chromosomal instability, GS genomic stability
Vega-Benedetti et al. Clinical Epigenetics          (2019) 11:100 Page 9 of 20
significantly more frequent in the group of tumours with
high methylation values (p value = 1.3E− 10). Interestingly,
the subgroup characterized by high β values in all CGIs
(within the dashed box) mainly included MSI samples (16
out of 24). To note, 22 out of 25 patients with Epstein-Barr
virus (EBV) infection clustered within the group of high
methylation values (Fig. 7), implying that EBV infection
was significantly more frequent in the group of highly
methylated samples (p value = 1.4E− 04). Furthermore,
paired samples with body/fundus localization pre-
sented lower mean Δβ values for each altered CGI
than the selected threshold (CpG 28 = 0.119, CpG
45 = 0.106, CpG 95 = 0.067 and CpG 22 = 0.130).
The in silico validation could not berelated to the
location (because only two control samples were
available).
PCDH alterations in biliary tract cancer
The study conducted in BTC did not detect any CGI dif-
ferentially methylated between BTC and matched nor-
mal samples according to our selection criteria.
Nevertheless, two CGIs (chr5:140787447-140788044,
CpG 45 and chr5:140797162-140797701, CpG 41),
showed significant Δβ values with adjusted p values and
were associated with two CTCF binding sites and pro-
moter regions (Fig. 8a, b, Table 4). As previously
mentioned, CpG 45 was altered in gastric cancer as well
(Table 4).
BTC samples were heterogeneous and included 20
gallbladder carcinomas and 22 intrahepatic and eight ex-
trahepatic cholangiocarcinomas. Hence, we analysed
each group separately and found significant differences
for these loci between intrahepatic cholangiocarcinomas
and extrahepatic cholangiocarcinomas/gallbladder car-
cinomas (Fig. 8b, Table 4).
UHC analysis showed a clear distinction between
normal and the majority of tumoral samples (68%)
and underlined the methylation differences among the
three tumoral localizations (Fig. 9). In fact, the major-
ity of the gallbladder (85%) and extrahepatic (87.5%)
samples clustered together in the branch of sole tu-
mours, while intrahepatic cholangiocarcinomas were
distributed almost equally between the two main
clusters.
The differential methylation of these CGIs was con-
firmed by the in silico methylation data (Δβ values =
0.370 and 0.278 for CpG 45 and CpG 41 respectively)
(Fig. 8c) although these cases included 33 intrahepatic
cholangiocarcinomas, two extrahepatic cholangiocarci-
nomas and one gallbladder cancer (TCGA-CHOL).
To note, the normal samples of our discovery dataset
included nine gallbladder and one extrahepatic tissues
with average β values of 0.185 (CpG 45) and 0.227
Fig. 7 Gastric in silico set unsupervised hierarchical clustering analysis based on the average methylation β value for each of the aberrantly
methylated CGI. Heatmap obtained by UHC of 248 gastric cancer samples. Two groups of GC branched separately according to their methylation
levels. A subgroup with high methylation values in all CGIs is enclosed in a dashed box. To the right of the heatmap, subtype information are
reported: MSI microsatellite instability, CIN chromosomal instability, GS genomic stability, EBV Epstein-Barr virus positivity
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Fig. 8 Methylation values obtained from the biliary tract cancer discovery dataset and the in silico dataset. a Genomic organization of PCDHG@,
including the localization of exons, CGIs (annotated with the UCSC CGI name) and CTCF binding sites. b Mean β values, resulting from the
average of the samples (normal and tumour) of each probe of the altered CGIs obtained using EPIC array. c Mean methylation values of each
probe, belonging to the CpG 45 and CpG 41, obtained from the in silico datasets TCGA-CHOL (450K array). Tumour: Gbc, gallbladder cancer; Extra
chol, extrahepatic cholangiocarcinoma; Intra chol, intrahepatic cholangiocarcinoma. Normal: Gb, gallbladder; Extra, extrahepatic; Intra, intrahepatic
Table 4 Altered CGIs in biliary tract cancer
UCSC CGI UCSC
CGI
name
CTCF binding
site
Δβ
value
(BTC-
control)
Δβ value
(Intrahepatic
chol-control)
Δβ value
(Extrahepatic
chol-control)
Δβ value
(Gallbladder
cancer-
control)
Δβ value
(Extrahepatic/
gallbladder-
control)
Genes within region Gene
promoter-
associated
CGI
chr5:140787447-
140788044
CpG
45
chr5:140786247-
140788714
0.175 0.104 0.212 0.235 0.229 PCDHGA1, PCDHGA2,
PCDHGA3, PCDHGA4,
PCDHGA5, PCDHGA6,
PCDHGA7, PCDHGA8,
PCDHGA9, PCDHGB1,
PCDHGB2, PCDHGB3,
PCDHGB4, PCDHGB5,
PCDHGB6
PCDHGB6
chr5:140797162-
140797701
CpG
41
chr5:140795962-
140798360
0.130 0.108 0.200 0.215 0.209 PCDHGA1, PCDHGA10,
PCDHGA2, PCDHGA3,
PCDHGA4, PCDHGA5,
PCDHGA6, PCDHGA7,
PCDHGA8, PCDHGA9,
PCDHGB1, PCDHGB2,
PCDHGB3, PCDHGB4,
PCDHGB5, PCDHGB6,
PCDHGB7
PCDHGB7
Note: CGI CpG island, BTC biliary tract cancer, chol cholangiocarcinoma. CpG 45 and 41 correspond to UCSC CGI name
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(CpG 41), while in silico normal samples included
eight intrahepatic and one extrahepatic tissues with
average methylation values of 0.078 (CpG 45) and
0.160 (CpG 41).
PCDH methylation pattern is not altered in chronic
lymphocytic leukemia
Interestingly, these clustered genes behaved differently
in a type of blood cancer, chronic lymphocytic leukemia,
analysed by our group. Analysis of our experimental and
in silico data (ICGC: CLLE-ES) did not reveal any sig-
nificant methylation aberrations in PCDH clusters (Add-
itional file 2: Table S1).
Further in silico analyses
To increase the robustness of our experimental results, we
explored the methylation status of the altered CGIs associ-
ated with C-type PCDHG in different cancers, using the
database MethHC (Fig. 10). As observed in Fig. 10a,
PCDHGC3 was significantly hypermethylated (Δβ value =
0.224) only in COAD. Differently, PCDHGC4 and
PCDHGC5 were commonly hypermethylated in a large
variety of tumours (Fig. 10b, c).
We tested whether the methylation alteration status of
N-shelf region or CGIs annotated in promoter regions (Ta-
bles 1, 2, 3 and 4) could be associated with change in the
expression pattern of the respective gene using TCGA-
LGG, TCGA-COADREAD, TCGA-STAD and TCGA-
CHOL data. We found a statistically significant negative
correlation between methylation and gene expression (Add-
itional file 3: Figure S2, Additional file 4: Figure S3, Add-
itional file 5: Figure S4 and Additional file 6: Figure S5)
except for CpG16 methylation and PCDHGB3 gene expres-
sion in TCGA-COAD (Additional file 4: Figure S3).
We also investigated the correlation between the methy-
lation status of the altered CGIs in the cancer types ana-
lysed in the current work and the overall survival using the
web-tool UCSC Xena. Therefore, the survival curves were
focused on the chromosome region, chr5:140750050-
140893189 altered in CRC; chr5:140762401-140864748 in
gastric cancer; chr5:140787447-140788044 in BTC; and
chr5:140865433-140870165 in low grade glioma (LGG)
(Fig. 11). Tumour samples were divided into high and low
methylation β values groups. The Kaplan Meier plots
showed a possible correlation only in LGG while the ana-
lyses did not reveal any significant differences between the
Fig. 9 Discovery set unsupervised hierarchical clustering analysis based on the average methylation β value for the two aberrantly methylated
CGIs. Heatmap obtained by UHC of 50 BTC samples and 10 matched normal samples. The UHC analysis clearly separated one group of sole
tumours and another group including normal and tumoral samples. To the right of the heatmap further information are reported: histology,
localization and grade. BTC, biliary tract cancer
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two groups of patients with high and low methylation
values in the other tumour types (Fig.11). In fact, in LGG,
we observed an abrupt decrease of the survival probability
in the first period of the survival time (x-axis) in patients
with low β values (blue line) (Fig. 11d). Therefore, we fo-
cused the analysis in the C-types PCDHGs (Fig. 12). Firstly,
the survival curves of each C-type isoform indicated that
the low methylation values of PCDHGC5 significantly cor-
relate with a decrease of survival probability in the first
period of this cancer type (Fig.12c). Secondly, the methyla-
tion level of each of the three isoforms, PCDHGC3,
PCDHGC4 and PCDHGC5, tended to negatively correlate
with their expression levels, suggesting that aberrant
methylation may be essential for their transcript regulation
in LGG (Fig. 11d).
Discussion
The epigenetic dysregulation of clustered PCDHs has
been associated with brain disorders and with cancer as
well [2]. In particular, the involvement of protocadherins
in different types of tumours has been studied by several
research groups [4, 16–18]. In the current experimental
study, the CGIs related to PCDH clusters were markedly
and significantly altered in the solid tumours analysed
(Table 5). We detected, with a high statistical power, sig-
nificant methylation alterations in CGIs associated with
clustered PCDHs that were successfully cross-validated
using a larger sample size from in silico TCGA datasets
(Fig. 2, Fig. 3 and Fig. 5). Interestingly, all the detected
altered regions, except CpG 19 and CpG 20, were associ-
ated with promoter regions. Since promoter choice is
regulated by DNA methylation [36] and the variable re-
gion of each gene cluster contains several CpG sites [8],
we analysed the correlation between methylation and ex-
pression of the altered CGIs mapping in promoter re-
gions. Interestingly, a negative correlation between
methylation and expression was detected (Additional
files 3: Figure S2, Additional file 4: Figure S3, Additional
Fig. 10 Box plots of the methylation values in tumour and normal tissues from different cancers, obtained from the in silico dataset TCGA.
Differential methylation (Δβ) values of the CGIs of PCDHGC3 (a), PCDHGC4 (b) and PCDHGC5 (c) were calculated between tumour and normal
tissues. BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical
adenocarcinoma, COAD colon adenocarcinoma, HNSC head and neck squamous cell carcinoma, KIRC kidney renal clear cell carcinoma, KIRP
kidney renal papillary cell carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma,
PAAD pancreatic adenocarcinoma, PRAD prostate adenocarcinoma, READ rectal adenocarcinoma, SARC sarcoma, SKCM skin cutaneous
melanoma, STAD stomach adenocarcinoma, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma
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file 5: Figure S4 and Additional file 6: Figure S5) except
for CpG16 and PCDHGB3 (Additional file 4: Figure S3).
Specific members of the PCDHG cluster were also ob-
served to be downregulated in CRC [4, 22]. Of note, des-
pite the different methylation and expression aberrations
within the clustered PCDHs, it should be taken into con-
sideration the concept remarked by Han et al. and Chen
and Maniatis that functional compensation is likely to
occur among these gene clusters [37, 38].
In addition, differential methylation of C-type mem-
bers of the PCDHG cluster was reported in silico in a
great variety of cancers (Fig. 10). To explore whether the
detected methylation alterations may also have an im-
pact on tumour prognosis, we examined a possible asso-
ciation between high or low differential methylation
values and the overall survival in silico (Fig. 11). The
plots in Fig. 11 exhibited a trend in the correlation be-
tween patients with different levels of β values and the
survival rate of LGG patients, while no association was
found in the gastrointestinal tumour types. Furthermore,
among the C-types PCDHG genes, PCHDGC5 showed
association with LGG survival probability (Fig. 12c) and
could be a predictive biomarker. However, in this cancer,
all C-type PCDHGs presented a significant negative cor-
relation between methylation values and expression
levels (Fig. 12d). In fact, as mentioned before, clustered
PCDHs are mainly expressed in the nervous system
while their expression is lower in other tissues [2, 39].
Thus, our results confirmed that hypermethylated genes
in cancer are already lowly expressed in the respective
normal tissues [25, 40, 41], while a tumour in a tissue with
high expression, as in this case of gliomas, can undergo
hypomethylation in this gene cluster. Finally, our experi-
mental discovery data and the in silico analyses indicated
that PCDH cluster genes undergo methylation pattern
changes during gastrointestinal tumorigenesis.
Fig. 11 In silico survival curves of patients with colon and rectal adenocarcinoma (a), stomach adenocarcinoma (b), cholangiocarcinoma (c) and
low grade glioma (d). The altered region detected in our research and used for this analysis is specified for each tumour type in the Kaplan-Meier
plots (x-axis, survival time in days; y-axis, survival probability). Samples were divided into high and low methlyation value groups
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The absence of significant methylation differences in
clustered PCDHs genes in CLL suggested that they are not
targeted by methylation during tumorigenesis in haemato-
logical neoplasms in contrast to solid tumours. An explan-
ation for this result could be related to the cell adhesion
function of PCDHs [1, 42] that is not essential in blood
cancer for cell contact and tumour mass formation. Be-
sides, our CLL analysis was also supported by the cross-
validation in silico that revealed similar Δβ values (Add-
itional file 2: Table S1). Further studies focused on other
blood cancers are needed to support this finding.
The analysis of our gliomas data revealed a hypomethy-
lation event (Δβ value = − 0.285) in the flanking region of
a CGI associated with the PCDHG cluster, including the
PCDHG C-type (Table 1). Although this hypomethylation
did not involve the CGI itself but a flanking region, a pre-
vious work highlights the importance of alterations in this
region in gene expression [43]. Supportive evidence was
provided by the survival analysis considering only the
flanking region of the CGI in LGG (Fig. 11d). This survival
curve indicated that in the low-β values group of patients
(blue line), the survival probability had an early reduction
compared to the high-β values group (Fig. 11d). Thus, this
hypomethylation event may have a prognostic implication
in PA samples. Moreover, at the expression level,
PCDHGs are essential during neuronal development and
their knockdown or deficiency leads to loss of different
neuronal cell types, synapse decrease or dendritic arbor-
isation decline [37, 44, 45]. Therefore, the hypomethyla-
tion event could lead to the upregulation of this group of
PCDHGs, suggesting that tumour cells need to behave as
progenitor cells, i.e. returning to the conditions required
during development. However, it should also be consid-
ered the possibility that the methylation status found in
the tumour actually mirrors the cell of origin pattern clon-
ally expanded [24, 40, 46–48]. In this case, it may not rep-
resent a cause or an effect of tumorigenesis, but still a
cancer-specific clustered PCDH methylation pattern
would remain a valuable biomarker. In addition, PCDHGs
overexpression could be implicated in cell survival due to
regulation of apoptotic signalling pathways [4] and inter-
action with cell-adhesion kinases [5, 49].
Fig. 12 In silico analyses using the dataset TCGA-LGG. Survival curves of patients classified by high and low methylation β values of PCDHGC3 (a),
PCDHGC4 (b) and PCDHGC5 (c). d Correlation between methylation and expression level of each PCDHG C-type
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Our experimental data showed that the CGIs of clus-
tered PCDHs in CRC are the most highly hypermethy-
lated among the gastrointestinal tumours analysed
(Tables 2, 3 and 4). UHC analysis revealed that all CRCs
clustered together separated from normal samples, with
the sole exception of sample 279T (Fig. 4), suggesting a
strong methylation alteration of clustered PCDHs in
CRC. Moreover, the hypermethylation of these CGIs
could be early events during carcinogenesis because they
are frequently found in our adenoma samples although
some of them did not present methylation alterations.
Of note, the Δβ value was always higher in CRCs than in
adenomas, except for the CGI located at chr5:
140750050-140750264 (CpG 16) (Table 2). As the values
we are referring to, were average values, the differences
observed between the two data sets could be due either
to increased degree of methylation of each involved is-
land in carcinomas compared to adenomas or to hyper-
methylation presence in more CRC samples than in
adenomas. In this regard, we specifically looked at the β
value for each sample for the selected islands. In fact,
when we analysed adenomas, we found that while few of
them branched nearby normal mucosa samples
(CTE1279, CTE1434 and CTE1620), the remaining ones
grouped on separated branches and some of them more
closely resembled the methylation pattern of carcinomas
(Fig. 4). To complement the analysis, we did not find
any correlation between PCDHs methylation alterations
and the grade of carcinogenesis in adenoma. In fact, as
we observed in Fig. 4, the adenomas clustered randomly
according to the disease grade.
Interestingly, our experimental methylation studies
showed that some CGI alterations were common in dif-
ferent cancers (gastric, biliary tract and colorectal can-
cer) and others were specific for each cancer-type but
they were all associated with the PCDHG cluster (Table
5). Interestingly, CpG 22, the most hypermethylated CGI
in CRC was also the most hypermethylated in GC. Since
this CGI was also hypermethylated in CRA indicating
that it is an early event in CRC tumorigenic, it is likely
that this event can occur early also during GC tumori-
genesis. Other studies have previously found methylation
alterations of PCDHG cluster in gastrointestinal tu-
mours, including colon cancer [4]. We did not detect
significant hypermethylation in the other two PCDH
clusters in contrast to Dallosso et al. These events could
be related to the wide expression of PCDHG cluster in
embryonic and adult tissues, while PCDHA cluster is
specifically expressed in the nervous system [4].
Furthermore, the detected methylation aberrations
seem to be frequent events in gastrointestinal tumours,
some involved in tissue-specific mechanisms and others
in common mechanisms. In particular, we found a differ-
ence in the methylation pattern of CpG 95 between
rectal and colon cancer samples suggesting that the
identified alteration may be specific of colon localization.
From a clinical point of view, this may be important be-
cause it could provide broad-spectrum and tissue-
specific tumour biomarkers. Similar differences among
localizations have been detected in GC and BTC sam-
ples. In fact, GC methylation analysis revealed that Δβ
values of all the four altered CGIs did not reach our dif-
ferential methylation threshold in paired samples local-
ized in body/fundus. BTC results showed differences in
Δβ values of two CGIs between localizations suggesting
that the detected methylation alterations might reach
higher β values in gallbladder/extrahepatic. It is import-
ant to mention that normal samples used in the current
study were localized in gallbladder/extrahepatic ducts.
Therefore, we cannot exclude that we did not observe
any alterations in intrahepatic tumours because of the
lack of their matched normal tissue samples. In fact, in
silico data, where most of tumoral and normal samples
had an intrahepatic localization, revealed marked methy-
lation alterations of both CGIs. Thus, future analyses
should be performed comparing tumoral samples to
their coupled normal localization.
We investigated whether other clinical characteristics
were associated with methylation alterations in the dif-
ferent cancers analysed, finding an association between
hypermethylation and MSI status only in GC as reported
by other authors [50, 51]. In fact, tumour samples with
MSI branched together except for 164PRH sample that
clustered along normal samples (Fig. 6). We successfully
validated these results using in silico TCGA-STAD
methylation data (Fig. 7). Moreover, in silico EBV-
positive samples displayed high methylation levels for
the altered CGIs. This result agrees with previous evi-
dence reported in TCGA-STAD cohort where EBV-
positive samples presented extreme CpG island methyla-
tor phenotype (CIMP) [52].
The association between molecular subtypes and
methylation values could be also observed in the
other gastrointestinal tumours. Due to the lack of
these molecular data for both our experimental and
in silico cohort, we could not evaluate a possible
association in BTC. Given that our CRC samples
clustered together in a group with high values for all
the altered CGI and included two MSI samples, no
association between methylation and MSI status can
be detected. Furthermore, our previous analysis of
TCGA-COAD and READ methylation data for 74
CGIs, including two PCDH-associated CGIs (CpG 19
and CpG 22), revealed that most CRC samples clus-
tered in the group of tumours displayed high β values
[25], confirming that high methylation levels of the
analysed CGI alterations are not related to different
molecular status.
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Importantly, we included in our methylation analyses
the position of the CTCF binding sites, possibly associ-
ated with the CGIs. As mentioned before, these sites are
most likely related to the clustered PCDHs transcription
through the formation of DNA loops mediated by CTCF
interactions [11, 15]. Since methylation regulates CTCF
binding [12], the methylation abnormalities detected in
our experimental results could avoid or modify the hub
formation by blocking the interaction between the CTCF
protein and the neighbouring binding sites, consequently
regulating PCDHG cluster transcription. Previous func-
tional studies [12, 14, 20] have already shown that DNA
methylation aberrations are associated to alteration of
CTCF binding to DNA.
This study, although suggesting the evaluation of the
clustered PCDH-associated CGIs methylation levels as a
tumour biomarker in different types of cancer, has some
limitations that can be overcome by more detailed future
studies. A technical limitation is certainly due to the use
of different types of arrays in the different cases, in par-
ticular, the 27K array for PAs, which therefore does not
allow us to draw more definitive conclusions in the op-
posite methylation patterns observed in pilocytic astro-
cytomas compared to gastrointestinal tumours. In fact,
further studies analysing DNA methylation alterations as-
sociated to PCDH cluster genes in additional brain tu-
mours are needed to confirm the correlation between
hypomethylation in cancer and normal tissue expression.
Furthermore, an aspect that is certainly worth investigat-
ing is the lack of an experimental expression analysis and
further functional analyses aimed to understand if and
how the identified methylation alterations play a role in
the tumorigenesis of the different tumours analysed.
Conclusions
Although several authors have conducted analyses in
clustered PCDHs, this work highlighted that methylation
alterations of PCDHG@ are among the most statistically
significant aberrations in solid cancers. Moreover, our
results suggest that in neuronal tissue, where PCDHs are
highly expressed, this gene cluster becomes hypomethy-
lated in pilocytic astrocytomas, while in tissues where
PCDHs are lowly expressed, this cluster is targeted by
DNA methylation. These epigenetic aberrations in the
CGIs associated to PCDHG@ genes could be useful to
consider specific members of this cluster as possible
biomarkers. Nevertheless, further research is necessary
to elucidate their function and their expression regula-
tion in each tumour type.
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